RU2020115915A - Бициклические сульфоны и сульфоксиды и способы их применения - Google Patents

Бициклические сульфоны и сульфоксиды и способы их применения Download PDF

Info

Publication number
RU2020115915A
RU2020115915A RU2020115915A RU2020115915A RU2020115915A RU 2020115915 A RU2020115915 A RU 2020115915A RU 2020115915 A RU2020115915 A RU 2020115915A RU 2020115915 A RU2020115915 A RU 2020115915A RU 2020115915 A RU2020115915 A RU 2020115915A
Authority
RU
Russia
Prior art keywords
pyrrolo
dihydro
fluoro
triazole
phenyl
Prior art date
Application number
RU2020115915A
Other languages
English (en)
Russian (ru)
Other versions
RU2020115915A3 (https=
Inventor
Снахель Патель
Грегори ГАМИЛЬТОН
Крейг СТИВАЛА
Хуэйфэнь Чэнь
Блейк ДАНИЭЛС
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2020115915A publication Critical patent/RU2020115915A/ru
Publication of RU2020115915A3 publication Critical patent/RU2020115915A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2020115915A 2017-10-31 2018-10-30 Бициклические сульфоны и сульфоксиды и способы их применения RU2020115915A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579392P 2017-10-31 2017-10-31
US62/579,392 2017-10-31
PCT/EP2018/079772 WO2019086494A1 (en) 2017-10-31 2018-10-30 Bicyclic sulfones and sulfoxides and methods of use thereof

Publications (2)

Publication Number Publication Date
RU2020115915A true RU2020115915A (ru) 2021-12-01
RU2020115915A3 RU2020115915A3 (https=) 2022-05-06

Family

ID=64051580

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020115915A RU2020115915A (ru) 2017-10-31 2018-10-30 Бициклические сульфоны и сульфоксиды и способы их применения

Country Status (21)

Country Link
US (2) US11072617B2 (https=)
EP (1) EP3704097B1 (https=)
JP (1) JP2021501183A (https=)
KR (1) KR20200083515A (https=)
CN (1) CN111278809B (https=)
AR (1) AR113811A1 (https=)
AU (1) AU2018360270A1 (https=)
BR (1) BR112020008446A2 (https=)
CA (1) CA3078688A1 (https=)
CL (1) CL2020001062A1 (https=)
CO (1) CO2020003475A2 (https=)
CR (1) CR20200168A (https=)
IL (1) IL273847A (https=)
MA (1) MA50503A (https=)
MX (1) MX2020003451A (https=)
PE (1) PE20211247A1 (https=)
PH (1) PH12020550537A1 (https=)
RU (1) RU2020115915A (https=)
SG (1) SG11202002877RA (https=)
TW (1) TW201922748A (https=)
WO (1) WO2019086494A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
BR112020000771A2 (pt) 2017-07-14 2020-07-14 F. Hoffmann-La Roche Ag compostos de cetona bicíclica e métodos de uso dos mesmos
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CN113302193A (zh) 2019-01-11 2021-08-24 豪夫迈·罗氏有限公司 双环吡咯并三唑酮化合物及其使用方法
TW202214617A (zh) 2020-06-02 2022-04-16 法商賽諾菲公司 作為ripk1抑制劑之異㗁唑啶及其用途
JP2024544533A (ja) 2021-11-11 2024-12-03 ジェンザイム・コーポレーション Ripk1阻害剤としてのイソオキサゾリジン及びその使用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) * 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
CA2293400A1 (en) * 1997-06-13 1998-12-17 Gerald Mcmahon Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002322720B2 (en) 2001-07-25 2008-11-13 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
JP2006526015A (ja) 2003-05-02 2006-11-16 エラン ファーマシューティカルズ,インコーポレイテッド 炎症疾患治療のためのブラジキニンb1受容体アンタゴニストとしての4−ブロモ−5−(2−クロロ−ベンゾイルアミノ)−1h−ピラゾール−3−カルボン酸アミド誘導体および関連化合物
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
CN104271566B (zh) 2012-05-22 2017-05-31 霍夫曼-拉罗奇有限公司 取代的联吡啶胺及其用途
JP6199991B2 (ja) 2013-01-18 2017-09-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 3置換ピラゾール及びdlk阻害剤としての使用
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
AR096151A1 (es) 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
JP6523251B2 (ja) 2013-05-01 2019-05-29 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft C−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
CN107406462B (zh) 2015-03-09 2020-11-10 豪夫迈·罗氏有限公司 三环dlk抑制剂及其用途
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
EP3317269B1 (en) 2015-07-02 2022-09-21 F. Hoffmann-La Roche AG Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
US10751444B2 (en) 2015-08-07 2020-08-25 Victor Matthew Phillips Flowable hemostatic gel composition and its methods of use
WO2017096301A1 (en) * 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
IL287136B2 (en) * 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
CN110267949A (zh) 2016-11-08 2019-09-20 塞科里昂医疗股份有限公司 sGC刺激剂
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
BR112020000771A2 (pt) 2017-07-14 2020-07-14 F. Hoffmann-La Roche Ag compostos de cetona bicíclica e métodos de uso dos mesmos
RU2020114670A (ru) 2017-10-11 2021-11-12 Ф. Хоффманн-Ля Рош Аг Бициклические соединения для применения в качестве ингибиторов rip1 киназы
AR113811A1 (es) 2017-10-31 2020-06-10 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos

Also Published As

Publication number Publication date
EP3704097B1 (en) 2023-10-25
US11072617B2 (en) 2021-07-27
WO2019086494A1 (en) 2019-05-09
PH12020550537A1 (en) 2021-03-22
RU2020115915A3 (https=) 2022-05-06
SG11202002877RA (en) 2020-04-29
AU2018360270A1 (en) 2020-03-26
CR20200168A (es) 2020-07-12
US20230002391A1 (en) 2023-01-05
BR112020008446A2 (pt) 2020-12-29
IL273847A (en) 2020-05-31
EP3704097A1 (en) 2020-09-09
CN111278809A (zh) 2020-06-12
AR113811A1 (es) 2020-06-10
PE20211247A1 (es) 2021-07-13
US20190127382A1 (en) 2019-05-02
CN111278809B (zh) 2024-06-25
MX2020003451A (es) 2020-08-03
CL2020001062A1 (es) 2020-08-21
CO2020003475A2 (es) 2020-04-24
TW201922748A (zh) 2019-06-16
MA50503A (fr) 2020-09-09
JP2021501183A (ja) 2021-01-14
CA3078688A1 (en) 2019-05-09
KR20200083515A (ko) 2020-07-08
EP3704097C0 (en) 2023-10-25
US12338241B2 (en) 2025-06-24

Similar Documents

Publication Publication Date Title
RU2020115915A (ru) Бициклические сульфоны и сульфоксиды и способы их применения
JP2021501183A5 (https=)
JP2019537571A5 (https=)
RU2020114670A (ru) Бициклические соединения для применения в качестве ингибиторов rip1 киназы
CN104781255B (zh) 作为trka激酶抑制剂的n‑吡咯烷基、n’‑吡唑基‑脲、硫脲、胍和氰基胍化合物
IL324078A (en) Fused ring compounds
RU2486181C2 (ru) Пиримидилциклопентаны как ингибиторы акт-протеинкиназ
JP2013523884A5 (https=)
JP2020536915A5 (https=)
JP2023505258A5 (https=)
JP2018530571A5 (https=)
JP2014526549A5 (https=)
JP2010533158A5 (https=)
US10072003B2 (en) Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use
EP3247692A1 (en) Inhibitors of trka kinase
JP2016523911A5 (https=)
ES2543904T9 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
JP2020526549A5 (https=)
JP2014062093A5 (https=)
RU2016141088A (ru) 5-замещённые индазол-3-карбоксамиды и их получение и применение
EA034931B1 (ru) Индолкарбоксамидные соединения
RU2015135891A (ru) Новые производные пиразола
JP2017519021A5 (https=)
RU2013155456A (ru) Соединения пирролидинилмочевины и пирролидинилтиомочевины как ингибиторы киназы trka
TW201718536A (zh) 可作為TNFα調節劑之雜環化合物